interleukin-2-conjugated lipid nanoparticles

Interleukin-2-conjugated lipid nanoparticles (IL2-LNPs) are an investigational targeted mRNA delivery platform designed for in vivo regulatory T cell (Treg) immunotherapy. Developed by researchers at the University of Pennsylvania, these lipid nanoparticles are surface-conjugated with interleukin-2 (IL-2) using a SATA-maleimide-based strategy. This conjugation exploits the constitutively high expression of the high-affinity IL-2 receptor (specifically CD25) on Tregs to facilitate selective uptake of the mRNA-LNP cargo. In preclinical models, IL2-LNPs have demonstrated highly selective and efficient delivery of mRNA to Tregs in the spleen, lymph nodes, and blood, with minimal background uptake by other immune cell subsets. This platform is being investigated for its potential to transiently enhance or alter Treg function in situ for the treatment of autoimmune diseases, such as type 1 diabetes.

Other names

IL-2-LNPIL2-LNPIL 2-LNPIL-2-LNPsIL2-LNPsIL 2-LNPsIL-2-conjugated lipid nanoparticlesIL2-conjugated lipid nanoparticlesIL 2-conjugated lipid nanoparticlesinterleukin-2-conjugated mRNA-lipid nanoparticlesinterleukin2-conjugated mRNA-lipid nanoparticlesinterleukin 2-conjugated mRNA-lipid nanoparticles